Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints
Background People living with human immunodeficiency virus (PLHIV) have a 25-35–fold higher chance of being diagnosed with squamous-cell carcinoma of the anal canal (SCAC). Patients and methods We prospectively evaluated the safety and efficacy of retifanlimab in PLHIV and SCAC enrolled in the POD1UM-202 and POD1UM-303/InterAACT-2 studies; PLHIV with CD4+ cell count ≥200/μl and undetectable viral load were enrolled and continued on highly active antiretroviral therapy (HAART). HIV viral load and CD4+ cell counts were assessed every 8 weeks and could be reduced to every 6 months during safety and disease follow-up. Results Among the 20 patients with HIV enrolled, median age was 58 years, 70% were male, and 80% white. Nine patients received retifanlimab monotherapy and six patients received retifanlimab + platinum-based chemotherapy; five patients received placebo + chemotherapy. No consistent overall trend in CD4+ cell counts or loss of HIV control was observed; no treatment-emergent opportunistic infections were recorded. Immune-related adverse events were consistent among patients without HIV. Efficacy was broadly consistent across the overall study populations. Patient-reported outcomes showed no negative impact. Retifanlimab pharmacokinetics were independent of HIV status and not impacted by HAART. Conclusions This prospective evaluation, the first in PLHIV and SCAC, demonstrates that the efficacy of retifanlimab is qualitatively consistent with that in HIV-negative patients with no excess toxicity or reduced HIV control, supporting the inclusion of HIV-positive patients in immunotherapy trials.
Authors
- Pauline Rochefort (ORCID: https://orcid.org/0000-0003-4734-6896)
- Jean‐Philippe Spano (ORCID: https://orcid.org/0000-0002-3921-2479)
- L. Evesque
- M. Guillot Morales (ORCID: https://orcid.org/0000-0001-7509-146X)
- M. C. Munteanu
- Sara Lonardi (ORCID: https://orcid.org/0000-0002-7593-8138)
- Anderley Gordon (ORCID: https://orcid.org/0009-0006-2643-2196)
- Federica Morano (ORCID: https://orcid.org/0000-0002-5306-3596)
- Duncan Charles Gilbert (ORCID: https://orcid.org/0000-0003-1859-7012)
- Frank Van Fraeyenhove
- Michel Pierre Ducreux (ORCID: https://orcid.org/0000-0001-8649-7449)
- Edward Jae-Hoon Kim (ORCID: https://orcid.org/0000-0002-8660-7465)
- A. Vozy
- X. Xu
- M. Jones
- J. Capdevila
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Léon Bérard (FR)
- Istituto Oncologico Veneto (IT)
- ZNA Middelheim Hospital (BE)
- Royal Marsden Hospital (GB)
- Pitié-Salpêtrière Hospital (FR)
- Vall d'Hebron Hospital Universitari (ES)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- Centre Antoine Lacassagne (FR)
- Hospital Universitario Son Espases (ES)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Vall d'Hebron Institute of Oncology (ES)
- UC Davis Comprehensive Cancer Center (US)
- University College London (GB)
- Incyte (United States) (US)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1016/j.esmogo.2026.100441
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Incyte